Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule
-
Wed, 06-Sep-2023
- Posted by: Biocon Biologics
No Comments
Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%
-
Thu, 10-Aug-2023
- Posted by: Biocon Biologics
Biocon Biologics Announces Key Leadership Appointments
-
Fri, 04-Aug-2023
- Posted by: Biocon Biologics
Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
-
Mon, 24-Jul-2023
- Posted by: Biocon Biologics
U.S. FDA Completes Two cGMP Inspections at Biocon Biologics Insulins Facility in Malaysia
-
Fri, 21-Jul-2023
- Posted by: Biocon Biologics
Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries
-
Wed, 05-Jul-2023
- Posted by: Biocon Biologics
After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States
-
Mon, 03-Jul-2023
- Posted by: Biocon Biologics
Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign
-
Fri, 30-Jun-2023
- Posted by: Biocon Biologics
Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
-
Tue, 23-May-2023
- Posted by: Biocon Biologics
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
-
Fri, 28-Apr-2023
- Posted by: Biocon Biologics
